Shares of Illumina, Inc. (NASDAQ:ILMN) traded down 16.1% on Friday after Cowen lowered their price target on the stock from $380.00 to $320.00. Cowen currently has an outperform rating on the stock. Illumina traded as low as $303.92 and last traded at $305.05, 8,474,345 shares were traded during trading. An increase of 742% from the average session volume of 1,006,871 shares. The stock had previously closed at $363.66.
A number of other research analysts have also weighed in on ILMN. OTR Global lowered Illumina to a “positive” rating in a report on Tuesday, April 2nd. Deutsche Bank upped their price objective on Spirit Airlines from $75.00 to $79.00 and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research lowered GasLog Partners LP Unit from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 2nd. BidaskClub upgraded Zumiez from a “sell” rating to a “hold” rating in a research report on Saturday, June 22nd. Finally, Bank of America started coverage on Zai Lab in a research report on Friday. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $341.15.
In related news, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $321.96, for a total transaction of $1,062,468.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 124 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $371.29, for a total value of $46,039.96. The disclosure for this sale can be found here. Insiders have sold 55,991 shares of company stock worth $18,216,784 over the last quarter. 0.38% of the stock is currently owned by company insiders.
The stock has a fifty day simple moving average of $344.08. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $44.84 billion, a PE ratio of 53.33, a price-to-earnings-growth ratio of 2.59 and a beta of 1.15.
Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.34 by $0.26. The company had revenue of $846.00 million during the quarter, compared to analysts’ expectations of $838.70 million. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.45 EPS. On average, research analysts forecast that Illumina, Inc. will post 6.68 EPS for the current year.
About Illumina (NASDAQ:ILMN)
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Catch-Up Contributions
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.